Neurotrophic factor comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-03-20. Where a claim depends on a specific study, the study is described rather than over-claimed.
Animal studies have examined behaviour in tests of anxiety, memory retention and stress response, and several report changes in neurotrophic or neurotransmitter-related markers. The human evidence base is much smaller, consisting mainly of short trials conducted in Russia with limited reporting in English-language journals. Sample sizes are modest and outcome measures vary between studies, so the findings are best described as preliminary. Independent replication under modern trial standards has not been widely reported.
Outside its country of origin the compound is generally handled as a research chemical rather than an approved medicine. No regulatory approval from the United States Food and Drug Administration or the European Medicines Agency has been granted for human use. Identity and purity are normally checked by reverse-phase high-performance liquid chromatography, with mass spectrometry used to confirm the molecular mass. Lyophilised material is stored cold and desiccated, and repeated freeze-thaw cycles are avoided.
Published work on this peptide almost always uses intranasal delivery, with drops or a spray applied to the nasal mucosa. Some animal experiments have used subcutaneous or intraperitoneal injection, and a smaller number have compared routes directly. Oral administration is not a focus of the literature, because short peptides of this size are broken down by digestive enzymes and cross intestinal barriers poorly. How much of an intranasal dose reaches the bloodstream intact in humans remains an open question.
Reported pharmacological effects center on reduced anxiety-like behavior in animal models and on measures of memory and learning. Proposed contributing mechanisms include modulation of GABAergic signaling, shifts in monoamine turnover, and changes in the activity of enzymes that degrade neuropeptides. Effects on the expression of genes linked to neuroplasticity have also been described. No single molecular target is widely accepted, and whether the behavioral findings arise from one pathway or several remains an open question.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed as a stabilized analogue of tuftsin, a naturally occurring tetrapeptide fragment derived from the immunoglobulin heavy chain. The additional Pro-Gly-Pro segment at the carboxyl terminus is intended to slow enzymatic cleavage. The compound is usually described in the literature as a synthetic peptide with anxiolytic and cognitive-related activity, a label that reflects a research context rather than an approved therapeutic category.
Most published work on selank originates from a small number of research groups in the Russian Federation. A large share of that record appears in Russian-language journals, which limits access for readers who rely on English-indexed databases. Independent replication by laboratories outside the original research network is sparse in publicly available sources. This concentration of origin and language is a frequently noted feature when the compound is summarized in broader reviews of synthetic peptides.
| Property | Value | Notes |
|---|---|---|
| Common route | Intranasal | Also injected in some animal work |
| Solubility class | Freely soluble in water | Solid form is hygroscopic |
| Typical storage | About -20 degrees Celsius | Keep desiccated and dark |
| Purity method | Reverse-phase HPLC | Reported as area percent |
| Confirmatory method | Mass spectrometry | Verifies expected molecular mass |
Pharmacokinetic data are limited. Like most short peptides, Selank is vulnerable to plasma and tissue peptidases, and its measured half-life in circulation is short, on a minutes scale. The Pro-Gly-Pro tail slows this degradation but does not eliminate it. Intranasal administration is the route described in most reports, with absorption through the nasal mucosa and a hypothesized path into the central nervous system that avoids the blood-brain barrier. Direct measurements of human brain exposure are unavailable, so distribution claims rest on inference from animal work.
Clinical evidence comes mainly from small studies conducted in Russia, several of which were open-label or lacked robust blinding. Reported outcomes include lower anxiety scores, changes in attention measures, and effects on asthenic states following illness. Sample sizes are typically in the tens of participants, and independent replication outside the region is scarce. Reviews published in English generally note the limited methodological quality of the underlying trials. Whether the compound produces clinically meaningful effects under rigorous conditions remains unresolved.
Selank is a hydrophilic peptide and dissolves readily in water and in aqueous buffers. The lyophilised powder is typically a white to off-white solid. Because short peptides are prone to hydrolysis and oxidation, handling benefits from limiting exposure to heat, moisture and strong light. Working solutions are commonly prepared in sterile water or saline, and repeated freeze-thaw cycles are avoided to reduce aggregation and loss of activity. These practices reflect general laboratory convention rather than published stability specifications.
Dry powder is normally held at -20 degrees Celsius or lower, in a sealed container with desiccant and protection from light. Reconstituted solutions are usually kept at 2 to 8 degrees Celsius for short periods and frozen for longer ones. Proline residues at several positions are generally associated with some resistance to peptidase attack, but chemical stability still declines at neutral to alkaline pH and at elevated temperature. Exact shelf-life figures are product-specific and are not standardised across suppliers.
Selank is studied chiefly as an animal-model anxiolytic with proposed secondary effects on memory and immune signaling. Reported mechanisms include modulation of the GABA-A receptor complex, inhibition of enkephalin-degrading enzymes, and shifts in monoamine turnover within limbic structures. Some experiments describe increased expression of brain-derived neurotrophic factor in the hippocampus after repeated dosing. No single molecular target has been confirmed, and the peptide does not bind any receptor with the selectivity typical of a conventional small-molecule drug. Mechanism therefore remains a set of hypotheses rather than an established pathway.
Laboratory work relies on standard behavioral paradigms. Rodents are tested in the elevated plus maze, open field, and passive avoidance tasks, with outcomes compared against diazepam or vehicle controls. Intranasal dosing is used most often because it bypasses first-pass metabolism, though intraperitoneal and intravenous routes also appear in published protocols. Biochemical endpoints include tissue BDNF concentrations, cytokine levels, and monoamine metabolites. Human data are limited to small Russian trials reporting reduced anxiety scores; most were not prospectively registered, and few employed independent outcome assessment.
Measuring peptide exposure inside the brain is technically difficult. Selank is degraded rapidly in plasma, and assays must separate intact peptide from fragments, which favors targeted mass spectrometry over immunoassays alone. Reported half-lives are short, on the order of minutes, so effects observed hours later are attributed to downstream signaling rather than to the parent compound. Blood-brain barrier permeability is debated and rarely quantified directly. Gaps include absent dose-response characterization, inconsistent reporting of purity, and almost no pharmacokinetic data from human participants.
I took him along to a training camp in Spain. The boy changed then into a sort of lion. He raced around as though he was powered by rockets. I went to talk to him. He was really happy he was riding well and he told me to look out for him. I asked if he wasn't perhaps "using something" and he jumped straight up, climbed on a chair and from deep inside a cupboard he pulled out a plastic bag full of pills. I felt my heart skip a beat. I had never seen so many fireworks together. With a soigneur we counted the pills: there were 5,000 of them, excluding hormone preparations and sleeping pills. I took them away, to his own relief. I let him keep the hormones and the sleeping pills. Later he seemed to have taken too many at once and he slept for a couple of days on end. We couldn't wake him up. We took him to hospital and they pumped out his stomach. They tied him to his bed to prevent anything going wrong again. But one way or another he had some stimulant and fancied taking a walk. A nurse came across him in the corridor, walking along with the bed strapped to his back. Currently modafinil is being used throughout the sporting world, with many high-profile cases attracting press coverage as prominent United States athletes have failed tests for this substance. Some athletes who were found to have used modafinil protested as the drug was not on the prohibited list at the time of their offence, however, the World Anti-Doping Agency (WADA) maintains it is a substance related to those already banned, so the decisions stand.
=== Synonymous mutation of bases === When an incorrect nucleotide is inserted during replication or transcription of a coding region, it can affect the eventual translation of the sequence into amino acids. Since multiple codons are used for the same amino acids, a change in a single base may still lead to translation of the same amino acid. This phenomenon is referred to as degeneracy and allows for a variety of codon combinations leading to the same amino acid being produced. For example, the codes TCT, TCC, TCA, TCG, AGT, and AGC all code for the amino acid serine. This can be explained by the wobble concept. Francis Crick proposed this theory to explain why specific tRNA molecules could recognize multiple codons. The area of the tRNA that recognizes the codon called the anticodon is able to bind multiple interchangeable bases at its 5' end due to its spatial freedom. A fifth base called inosine can also be substituted on a tRNA and is able to bind with A, U, or C. This flexibility allows for changes in bases in codons leading to translation of the same amino acid. The changing of a base in a codon without the changing of the translated amino acid is called a synonymous mutation. Since the amino acid translated remains the same a synonymous mutation has traditionally been considered a neutral mutation. Some research has suggested that there is bias in selection of base substitution in synonymous mutation. This could be due to selective pressure to improve translation efficiency associated with the most available tRNAs or simply mutational bias.
== Constituents == A clear liquid (sometimes there is a deposit consisting of waxes) in color from green to greenish yellow, bergamot essential oil consists of a volatile fraction (average 95%) and a non-volatile fraction (5% or residual). Chemically, it is a complex mixture of many classes of organic substances, particularly in the volatile fraction, including terpenes, esters, alcohols and aldehydes, and for the non-volatile fraction, oxygenated heterocyclic compounds as coumarins and furanocoumarins.
== Nutrition == NATO bases the nutritional content requirement on a reference soldier weighing 79 kg (174 lb), who on normal operations would have an energy expenditure of approximately 3,600 kcal per day. For combat operations, energy expenditure is estimated to be 4,900 kcal per day; however, this is seen to be a worst-case scenario.
The Dexcom G5 was the first Dexcom continuous glucose monitor to be compatible with a mobile application. The accompanying app, named "Dexcom G5," allowed users to view their blood glucose readings on a smartphone and, with an intermediary iPhone, on an Apple Watch. The app remained available until the discontinuation of the Dexcom G5, at which point it was removed from app stores. The Dexcom G6 continued this functionality with its own dedicated application, "Dexcom G6," which provided real-time glucose readings and data-sharing capabilities. Upon the release of the Dexcom G7, a new application, "Dexcom G7," was introduced to support the updated system. The Dexcom G7 app is also available as the first system that connects directly to a smart watch. The Stelo by Dexcom also has an app which is similar to that of the G7, but has slightly different options.
Sources: en.wikipedia.org
Copper-64 (64Cu) is a positron- and beta-emitting isotope of copper (exhibiting both forms of beta decay), with applications in molecular radiotherapy and positron emission tomography. Its unusually long half-life (12.7 hours) for a positron-emitting isotope makes it increasingly useful when attached to various ligands for PET and PET-CT scanning.
=== Digital infrastructure === Although a few digital technologies can operate in areas with limited mobile phone coverage and internet connectivity, rural network coverage plays an important role in digital agriculture's success.
== History == 2C-B, the first major 2C drug and an analogue of mescaline, was first described by Alexander Shulgin in the 1970s. Richard Glennon and colleagues synthesized and described 25B-NB (N-benzyl-2C-B) along with a variety of other 25-NB derivatives in 1994. It was observed at the time that 25B-NB had slightly higher affinity for the serotonin 5-HT2A receptor than 2C-B and that other 25-NB derivatives with substituents on the benzyl ring showed very high affinity for the receptor, though functional data were not reported. N-Benzyl derivatives of the ketanserin-related quinazolinedione EZS-8, such as RH-34, were first described by Heinz Pertz, Sigurd Elz, and Ralf Heim by 1996 or 1998. NBOMe-mescaline and NBOMe-escaline were first described by Pertz and colleagues by 1999, while 25B-NBOMe was first described by Heim and colleagues in 1999. 25I-NBOMe and other 25-NB compounds such as 25TFM-NBOMe and 2CBFly-NBOMe were described by Heim and colleagues by 2000. 25I-NBOMe and other 25-NB drugs were subsequently further described by Heim in his dissertation in 2003. 25C-NBOMe was not described in the literature until 2010. The discovery of the 25-NB compounds by Heim and colleagues has been described by David E. Nichols as structurally remarkable, since N-alkylation of psychedelic phenethylamines, for instance Beatrice (N-methyl-DOM), has otherwise invariably abolished the hallucinogenic effects of this class of compounds.
=== Patient information === Blood Transfusion Leaflets (NHS Blood and Transplant) Blood Transfusion Leaflets (Welsh Blood Service) Blood Transfusion Information (Scotland) Blood Transfusion Information (Australia) Blood Transfusion Information (American Cancer Society)
Sources: en.wikipedia.org
==== 100–199 ==== Air Fares (Amendment) Regulations 1993 (S.I. 1993/100) Licensing of Air Carriers (Amendment) Regulations 1993 (S.I. 1993/101) Local Government and Housing Act 1989 (Commencement No. 15) Order 1993 (S.I. 1993/105) Education (School Financial Statements) (Prescribed Particulars etc.) Regulations 1993 (S.I. 1993/113) Teachers' Superannuation (Amendment) Regulations 1993 (S.I. 1993/114) British Railways (Penalty Fares) Act 1989 (Activating No. 8) Order 1993 (S.I. 1993/115) A31 Trunk Road (Ashley Heath Grade Separated Junction) Order 1993 (S.I. 1993/116) Local Government Act 1988 (Defined Activities) (Exemption) (Boothferry Borough Council) Order 1993 (S.I. 1993/117) Act of Sederunt (Fees of Messengers-at-Arms) 1993 (S.I. 1993/118) Value Added Tax (General) (Amendment) Regulations 1993 (S.I. 1993/119) Act of Sederunt (Fees of Sheriff Officers) 1993 (S.I. 1993/120) Testing in Primary Schools (Scotland) Revocation Regulations 1993 (S.I. 1993/121) East Birmingham Hospital National Health Service Trust (Change of Name) Order 1993 (S.I. 1993/122) Teddington Memorial Hospital National Health Service Trust (Establishment) Order 1993 (S.I. 1993/123) Revenue Support Grant (Specified Bodies) (Amendment) Regulations 1993 (S.I. 1993/139) A35 Trunk Road (40 mph Speed Limit) Order 2003 (S.I. 1993/142) Food Protection (Emergency Prohibitions) (Oil and Chemical Pollution of Fish) (No.2) Order 1993 (S.I. 1993/143) Council Tax (Additional Provisions for Discount Disregards) (Amendment) Regulations 1993 (S.I. 1993/149) Council Tax (Exempt Dwellings) (Amendment) Order 1993 (S.I.
Amanita virosa is a species of fungus in the class Agaricomycetes. In the UK, it has the recommended English name of destroying angel and is known internationally as the European destroying angel. Basidiocarps (fruit bodies) are agaricoid (mushroom-shaped) and pure white with a ring on the stipe and a sack-like volva at the base. The species occurs in Europe and northern Asia. It was formerly reported from North America, but similar-looking American species like A. bisporigera and A. ocreata are distinct. As the name suggests, the destroying angel is poisonous.
Mescaline has a wide array of suggested medical usage, including treatment of depression, anxiety, PTSD, nicotine dependence, and alcoholism. However, its status as a Schedule I controlled substance in the Convention on Psychotropic Substances limits availability of the drug to researchers. Because of this, very few studies concerning mescaline's activity and potential therapeutic effects in people have been conducted since the early 1970s. However, the drug is under development by Journey Colab under the code name JOUR-5700 and by Biomind Labs under the code names BMND04, BMND06, and BMND09 for various medical applications, such as treatment of alcoholism.
Sources: en.wikipedia.org
Most published work uses intranasal application, either as drops or as a nasal spray. Injection routes appear in a smaller set of animal experiments. Oral use is uncommon in the literature because peptide breakdown and poor absorption limit this route.
Reported human trials are few, brief and originate mainly from one country. They describe effects on anxiety-related measures, but sample sizes are small and reporting is limited. The results are widely regarded as preliminary rather than confirmed.
Reverse-phase liquid chromatography is used to assess purity and separation of related impurities. Mass spectrometry confirms that the observed molecular mass matches the expected peptide. A certificate of analysis from the supplier is the usual document of record.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, designed as a metabolically stabilized analogue of the endogenous tetrapeptide tuftsin. It has been studied mainly against anxiety-related and cognitive endpoints rather than as an approved medicine in most jurisdictions.